cafepharmaDec 6, 2023
Merck KGaA's BTK inhibitor fails phase III MS studies-- Adherence to weight-loss drugs is far higher with Wegovy than older medicines --CVS drug pricing overhaul signals a broader industry shift --http://bit.ly/w28kSd #clinicaltrials #ms #multiplesclerosis #merckkgaa #wegovy #novonordisk #patientadherance #CVShealth #drugpricing #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
Cafepharma

Cafepharma is a site for the pharmaceutical/medical industry. Our scope includes pharmaceutical, device, biotech, laboratory, animal health, dental, etc. We have curated daily news headlines, active forums where users can post anonymously, job listings and more.

Cafepharma
Dominic TyerSep 21, 2023

Germany's Merck puts $1.3bn into AI drug development through new deals with Exscientia and BenevolentAI

https://pharmaphorum.com/news/merck-puts-13bn-ai-exscientia-benevolentai-deals

#pharma #pharmaindustry #AI #artificialintelligence #exscientia #benevolentAI #merck #MerckKGaA

Merck puts $1.3bn into AI via Exscientia, BenevolentAI deals

pharmaphorum